| [1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.DOI: 10.3322/caac.21262.
|
| [2] |
Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma[J]. Infect Dis Clin North Am, 2010, 24(4):899-919. DOI: 10.1016/j.idc.2010.07.004.
|
| [3] |
Mazzola A, Costantino A, Petta S, et al. Recurrence of hepatocellular carcinoma after liver transplantation:an update[J]. Future Oncol, 2015, 11(21):2923-2936. DOI: 10.2217/fon.15.239.
|
| [4] |
王征, 周俭.肝癌肝移植术后的综合治疗[J].中华肝脏病杂志, 2013, 21(5):324-325. DOI: 10.3760/cma.j.issn.1007-3418.2013.05.002.Wang
Wang Z, Zhou J. Combined modality therapy for recurrent hepatocellular carcinoma following liver transplantation[J]. Chin J Hepatol, 2013, 21(5):324-325. DOI: 10.3760/cma.j.issn.1007-3418.2013.05.002.
|
| [5] |
Fahrner R, Dondorf F, Ardelt M, et al. Liver transplantation for hepatocellular carcinoma -factors influencing outcome and disease-free survival[J].World J Gastroenterol, 2015, 21(42):12071-12082. DOI: 10.3748/wjg.v21.i42.12071.
|
| [6] |
彭志海, 孙红成.肝癌肝移植术后肝癌复发[J].中华消化外科杂志, 2016, 15(5):444-447. DOI: 10.3760/cma.j.issn.1673-9752.2016.05.009.Peng
Peng ZH, Sun HC. Hepatocellular carcinoma recurrence after liver transplantation[J]. Chin J Dig Surg, 2016, 15(5):444-447. DOI: 10.3760/cma.j.issn.1673-9752.2016.05.009.
|
| [7] |
Pommergaard HC, Burcharth J, Rosenberg J, et al. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: a systematic review and meta-analysis[J].Transplant Rev (Orlando), 2016, 30(3):171-177. DOI: 10.1016/j.trre.2016.03.001.
|
| [8] |
Hung CH, Chiu YC, Chen CH, et al. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target[J]. Biomed Res Int, 2014:486407. DOI: 10.1155/2014/486407.
|
| [9] |
Farid WR, Verhoeven CJ, de Jonge J, et al. The ins and outs of microRNAs as biomarkers in liver disease and transplantation[J]. Transpl Int, 2014, 27(12)1222-1232.DOI: 10.1111/tri.12379.
|
| [10] |
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2):281-297. doi: 10.1016/S0092-8674(04)00045-5
|
| [11] |
Ambros V. The functions of animal microRNAs[J].Nature, 2004, 431(7006):350-355. doi: 10.1038/nature02871
|
| [12] |
Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma[J].J Hepatol, 2012, 56(6):1371-1383. DOI: 10.1016/j.jhep.2011.11.026.
|
| [13] |
Zhu Z, Zhang X, Wang G, et al. Role of microRNAs in hepatocellular carcinoma[J]. Hepat Mon, 2014, 14(8):e18672. DOI: 10.5812/hepatmon.18672.
|
| [14] |
Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma[J]. J Hepatol, 2012, 56(1):167-175. DOI: 10.1016/j.jhep.2011.04.026.
|
| [15] |
Fu Y, Wei X, Tang C, et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma[J]. Oncol Lett, 2013, 6(6):1811-1815. DOI: 10.3892/ol.2013.1638.
|
| [16] |
Xie QY, Almudevar A, Whitney-Miller CL, et al. A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity[J]. BMC Med Genomics, 2016, 9:18. DOI: 10.1186/s12920-016-0179-4.
|
| [17] |
Liese J, Peveling-Oberhag J, Doering C, et al. A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation[J]. Transpl Int, 2016, 29(3):369-380. DOI: 10.1111/tri.12733.
|
| [18] |
Xu X, Ling Q, Wang J, et al. Donor miR-196a-2 polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation in a Han Chinese population[J]. Int J Cancer, 2016, 138(3):620-629. DOI: 10.1002/ijc.29821.
|
| [19] |
Li QG, Yang GS, Yang Q, et al. Disseminated tumor cells homing into rats' liver: a new possible mechanism of HCC recurrence[J]. World J Gastroenterol, 2004, 10(6):903-905. http://pubmedcentralcanada.ca/pmcc/articles/PMC4726996/
|
| [20] |
Morita K, Shirabe K, Taketomi A, et al. Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation[J]. Liver Transpl, 2016, 22(5):665-676. DOI: 10.1002/lt.24400.
|
| [21] |
Wu LM, Ji JS, Yang Z, et al. Oncogenic role of microRNA-423-5p in hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(6):613-618. doi: 10.1016/S1499-3872(15)60038-8
|
| [22] |
Feng J, Wang J, Chen M, et al. miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma[J]. Oncol Rep, 2015, 33(2):713-720. DOI: 10.3892/or.2014.3642.
|
| [23] |
Tan YL, Bai ZG, Zou WL, et al. miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2015, 39(3):359-365. DOI: 10.1016/j.clinre.2014.09.010.
|
| [24] |
Han ZB, Chen HY, Fan JW, et al. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation[J]. J Cancer Res Clin Oncol, 2012, 138(1):153-161. DOI: 10.1007/s00432-011-1076-z.
|
| [25] |
Hu G, Drescher KM, Chen XM. Exosomal miRNAs: biological properties and therapeutic potential[J]. Front Genet, 2012, 3:56. DOI: 10.3389/fgene.2012.00056.
|
| [26] |
Ng KT, Lo CM, Wong N, et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation[J]. Oncotarget, 2016, 7(15):19824-19839. DOI: 10.18632/oncotarget.7627.
|
| [27] |
Sugimachi K, Matsumura T, Hirata H, et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation[J]. Br J Cancer, 2015, 112(3):532-538. DOI: 10.1038/bjc.2014.621.
|
| [28] |
Park JK, Kogure T, Nuovo GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival[J]. Cancer Res, 2011, 71(24):7608-7616. DOI: 10.1158/0008-5472.CAN-11-1144.
|
| [29] |
Kota J, Chivukula RR, O'Donnell KA, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model[J].Cell, 2009, 137(6):1005-1017. DOI: 10.1016/j.cell.2009.04.021.
|
| [30] |
Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study[J]. J Hepatol, 2013, 59(1):59-66. DOI: 10.1016/j.jhep.2013.02.026.
|
| [31] |
Xu Y, Huang J, Ma L, et al. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways[J]. Cancer Lett, 2016, 371(2):171-181. DOI: 10.1016/j.canlet.2015.11.034.
|
| [32] |
Yang F, Zhang L, Wang F, et al. Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma[J]. Neoplasia, 2011, 13(7):590-600. doi: 10.1593/neo.11422
|
| [33] |
Xu J, Lin H, Li G, et al. The miR-367-3p increases sorafenib chemotherapy efficacy to suppress hepatocellular carcinoma metastasis through altering the androgen receptor signals[J]. Ebiomedicine, 2016, 12:55-67. DOI: 10.1016/j.ebiom.2016.07.013.
|
| [34] |
Cai D, He K, Chang S, et al. MicroRNA-302b enhances the sensitivity of hepatocellular carcinoma cell lines to 5-FU via targeting Mcl-1 and DPYD[J]. Int J Mol Sci, 2015, 16(10):23668-23682. DOI: 10.3390/ijms161023668.
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: